A striking variety of policy instruments are used in Victoria, Australia to achieve conservation objectives. These include highly active voluntary programmes, a variety of conservation grants, and a reverse auction for the provision of ecosystem services, known as EcoTender. An open question regarding such payments for ecosystem services (i.e. grants and tenders) is whether they achieve ‘additionality.’
This page contains all information relating to implementation of the OECD Anti-Bribery Convention in Australia.
This review particularly recommends shifting away from income taxation to indirect taxation, for instance by raising more revenue from the Goods and Services Tax.
The government’s current review of the federal system, focusing on both spending and tax responsibilities, is welcome, as is the “whole of government” approach to the process.
This publication contains statistics on fisheries in OECD member countries (with the exception of Austria, Israel and Slovenia) and some non-member economies (Argentina, Colombia, Latvia, Chinese Taipei, Thailand) from 2006 to 2013. Data provided concern fishing fleet capacity, employment in fisheries, fish landings, aquaculture production, recreational fisheries, government financial transfers, and imports and exports of fish.
English, PDF, 93kb
This country note from Going for Growth 2015 for Australia identifies and assesses progress made on key reforms to boost long-term growth, improve competitiveness and productivity and create jobs.
Permanent migration under Australia’s Migration and Humanitarian Programmes rose by 7.7% in 2012-13 with 214 000 visas issued.
Leaders of the G20 countries meeting at their Summit in Brisbane, Australia, have called on the OECD and IMF to monitor their commitment to boost economic growth and create jobs.
Mr. Angel Gurría was in Brisbane to attend the G20 Leaders' Summit on 15-16 November. Prior to the Summit, the Secretary-General attended a G20 Finance Ministers Meeting, as well as L20 and B20 meetings.
English, PDF, 527kb
This country profile describes in details the Australian pharmaceutical system, including decision-making processes for regulatory approval, reimbursement and pricing; assessment guidelines; institution and stakeholders involved and specific policies for new high cost drugs, when available.